Expect 10% Upside In Claris Lifesciences: Nirmal Bang
Vishal Manchanda, research analyst at Nirmal Bang Securities, says Claris Lifesciences would have around Rs 3,000 crore cash on its book once all the cash from the Baxter deal is received. The company would most likely distribute 80 per cent of the cash to shareholders, he adds.
